Now that value-based prices can be determined for drugs, insurers and policy makers can consider steps toward a value-driven pricing system that does not require Medicare negotiation, price setting, or mandates. What will be needed, however, is a shift toward providing an array of incentives to bolster the business case for drugmakers to sell their products at a price in alignment with the benefits to patients and sensitive to the potential budget effect on the entire health care system.
Read Full Article »
